Tag Archives: Galantamine

Pharmacological Treatment of Dementia

General guidelines for psychotropic medication use in frail elderly patients are applicable. Systematic evidence to support the effectiveness of particular psychotropic drugs in dementia patients is limited. Therefore, choice of drug class may be based on clinical evidence, and choice of agent is often based on the side-effect profile and on the characteristics of a… Read More »

Alzheimer’s Disease Therapies

Current Therapies for Alzheimer’s Disease Because there is currently no cure for Alzheimer’s disease (), the primary goal of treatment remains the relief of cognitive, functional, and behavioral symptoms associated with the disease. Hence, current therapies aim to improve the quality of life for both Alzheimer’s disease patients and the caregivers who often must cope… Read More »

Alzheimer’s Therapy: Acetylcholinesterase Inhibitors

Overview. Acetylcholinesterase inhibitors are the only drugs approved for the treatment of mild to moderate Alzheimer’s disease in the major markets. acetylcholinesterase inhibitors do not cure Alzheimer’s disease but do alleviate the cholinergic deficit observed in Alzheimer’s disease patients. Cognitive symptoms are occasionally improved but most often are only stabilized by the drugs (). Studies… Read More »

Alzheimer’s Therapy: Galantamine

Galantamine (Shire/Janssen’s Razadyne) () is the most recent entrant in the Alzheimer’s disease market. Galantamine was approved for the treatment of mild to moderate Alzheimer’s disease in the United States and Europe in 2001. The agent is in Phase III clinical trials in Japan. Galantamine is currently in Phase III trials in the United States… Read More »

 Alzheimer’s Therapy: Rivastigmine

Rivastigmine (Novartis’s Exelon, Sigma Tau/Esteve’s Prometax) () is available in Europe and the United States, where it is indicated for mild to moderate Alzheimer’s disease. Development of rivastigmine in Japan has been discontinued. Novartis is evaluating rivastigmine for the treatment of moderate to severe Alzheimer’s disease in small clinical trials, although it is unclear if… Read More »

Information about Alzheimer’s Disease for Patients and Families

Alzheimer’s disease is the most common and well-known form of degenerative dementia. By definition, dementia is a syndrome, a cluster of symptoms, of impaired memory and cognition. Dementia is a cognitive disorder that impairs an individual’s memory and ability for reasoning, awareness, and judgment. Cognitive impairment in Alzheimer’s disease may involve disturbance of language (aphasia),… Read More »

Schizophrenia: Acetylcholinesterase Inhibitors

Three acetylcholinesterase inhibitors are on the market for the treatment of Alzheimer’s disease: Japan&Japan/Shire/Janssen’s galantamine (Reminyl), Eisai/Pfizer’s donepezil (Aricept), and Novartis’s rivastigmine (Exelon/Prometax). Clinical studies evaluating these agents in the treatment of the cognitive dysfunction and negative symptoms associated with schizophrenia have been performed, but only galantamine appears to be in commercial development for schizophrenia… Read More »

Schizophrenia: Serotonin-Dopamine Antagonists

Serotonin-dopamine antagonists, together with dopamine partial agonists, are considered atypical antipsychotics. serotonin-dopamine antagonists have been used for the treatment of schizophrenia since the early 1990s, and currently marketed serotonin-dopamine antagonists include Novartis’s clozapine (Clozaril/Leponex, generics), Janssen’s risperidone (Risperdal), Eli Lilly’s olanzapine (Zyprexa), AstraZeneca’s quetiapine (Seroquel), and Pfizer’s ziprasidone (Geodon/Zeldox). TABLE . Emerging Therapies in Development… Read More »

Assessment Of Treatment Response In Severe Dementia

The cholinesterase inhibitors donepezil, galantamine and rivastigmine enhance cholinergic neurotransmission and provide cognitive, functional and behavioural benefits in mild-to-moderate Alzheimer’s disease. Further data show donepezil to be effective in moderate-to-severe disease. Memantine, an NMDA-receptor antagonist, has been shown to be efficacious in moderate-to-severe Alzheimer’s disease and severe Alzheimer’s disease. Memantine positively influenced both cognitive and… Read More »